Zydus Cadila: Biosimilars Company Analysis

  • ABOUT THIS REPORT
    • Chapter structure
      • Strategic insight
      • Product analysis
      • Operating performance
      • Company introduction
    • Data sourcing
      • Analyst consensus
    • PharmaVitae Explorer database
  • EXECUTIVE SUMMARY
    • Zydus Cadila’s biosimilars overview
    • Zydus Cadila biosimilars SWOT analysis
      • Strengths
      • Weaknesses
      • Opportunities
      • Threats
    • Zydus Cadila biosimilars infrastructure
  • STRATEGIC INSIGHT
    • Zydus Cadila utilizes simple biologic products to gain market experience
    • A strong market position gives Zydus Cadila an advantage to expand its biosimilars portfolio globally…
    • …but international market entry will require partners
  • KEY PRODUCTS
    • Overview
    • Zydus Cadila biosimilar portfolio
    • EPO (erythropoietin)
      • Overview
      • Erythropoietin market size
      • Key competitors
      • Zydus Cadila biosimilar development
    • G-CSF and PEG G-CSF (filgrastim and pegfilgrastim)
      • Overview
      • Filgrastim and pegfilgrastim market size
      • Key competitors
    • IFN-A 2B and PEG IFN-A 2B (interferon alpha-2b and peginterferon alpha-2b)
      • Overview
      • Interferon alpha and peginterferon market size
      • Key competitors
      • Zydus Cadila biosimilar development
    • IFN-B 1B (interferon beta–1b)
      • Overview
      • Interferon beta market sizing
      • Key competitors
      • Zydus Cadila’s biosimilar development
    • Teriparatide (teriparatide)
      • Overview
      • teriparatide market size
      • Key competitors
    • Other pipeline copy-biologic/biosimilar candidates
  • OPERATING PERFORMANCE
    • Zydus Cadila’s financial performance over 2005–11
      • Operating costs and profit analysis, 2004–10
  • CORPORATE STRUCTURE
    • Background
    • Company structure
    • Deals and alliances
    • Recent developments
  • APPENDIX
    • References
      • Datamonitor reports
    • Biologic definitions
    • Exchange rates
  • TABLES
    • Table: Zydus Cadila – manufacturing and development metrics
    • Table: Zydus Cadila – biosimilar/copy-biologic portfolio
    • Table: Forecasted epoetin sales in the seven major markets ($m), 2011–16
    • Table: Zydus Cadila – pipeline and marketed biosimilar/copy-biologic epoetin drugs
    • Table: Zydus Cadila – biosimilar erythropoietin clinical trials
    • Table: Forecasted filgrastim and pegfilgrastim sales ($m), 2011–16
    • Table: Zydus Cadila – pipeline and marketed biosimilar/copy-biologic filgrastim and pegfilgrastim drugs
    • Table: Forecasted interferon alpha and peginterferon alpha sales ($m), 2011–16
    • Table: Zydus Cadila – pipeline and marketed biosimilar/copy-biologic filgrastim and pegfilgrastim drugs
    • Table: Zydus Cadila – biosimilar peginterferon alpha clinical trials
    • Table: Forecasted interferon beta sales ($m), 2011–16
    • Table: Zydus Cadila – pipeline and marketed biosimilar/copy-biologic interferon beta drugs
    • Table: Zydus Cadila – biosimilar interferon beta clinical trials
    • Table: Forecasted teriparatide sales ($m), 2011–16
    • Table: Zydus Cadila – pipeline biosimilar/copy-biologic teriparatide drugs
    • Table: Zydus Cadila – unspecified biosimilar/copy-biologic drugs in development
    • Table: Zydus Cadila operating revenue/cost analysis ($m), 2004–10
    • Table: Zydus Cadila – deal activity, 2010–12
    • Table: Exchange rates, 2011
  • FIGURES
    • Figure: The PharmaVitae Explorer
    • Figure: Zydus Cadila biosimilars overview
    • Figure: Zydus Cadila SWOT analysis
    • Figure: Zydus Cadila operating/cost performance ($m), 2005–11
    • Figure: Zydus Cadila – revenues by segment and geographic region, 2010–11

Report

Published by
Datamonitor
Published on
06 Jul 2012
Product code
HC00237-001
Pages
Please wait...

$2800

Multi-user License $7000